Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Tocilizumab in Cardiac Transplantation

ClinicalTrials.gov ID: NCT03644667

Public ClinicalTrials.gov record NCT03644667. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 6:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Targeting Inflammation and Alloimmunity in Heart Transplant Recipients With Tocilizumab (RTB-004)

Study identification

NCT ID
NCT03644667
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Enrollment
385 participants

Conditions and interventions

Interventions

  • Placebo Biological
  • Standard of Care Triple IS Drug
  • tocilizumab Biological

Biological · Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 19, 2018
Primary completion
Mar 24, 2025
Completion
Mar 24, 2025
Last update posted
Apr 6, 2026

2018 – 2025

United States locations

U.S. sites
20
U.S. states
13
U.S. cities
18
Facility City State ZIP Site status
Cedars Sinai Medical Center (CACS) Beverly Hills California 90211
University of California, San Diego: Sulpizio Cardiovascular Center (CASD) La Jolla California 92037
Stanford Health Care (CASU) Stanford California 94305
Tampa General Hospital (FLTG) Tampa Florida 33606
Northwestern Memorial Hospital (INLM) Chicago Illinois 60611
Tufts Medical Center (MANM) Boston Massachusetts 02111
Massachusetts General Hospital (MAMG) Boston Massachusetts 02114
St. Luke's Hospital of Kansas City (MOLH) Kansas City Missouri 64111
University of Nebraska Medical Center (NEUN) Omaha Nebraska 68198
Mount Sinai Medical Center (NYMS) New York New York 10029
Columbia University Medical Center (NYCP) New York New York 10032
Montefiore Medical Center (NYMA) The Bronx New York 10467
Duke University Medical Center (NCDU) Durham North Carolina 27710
Cleveland Clinic Foundation (OHCC) Cleveland Ohio 44195
Penn State Health: Milton S. Hershey Medical Center (PAHE) Hershey Pennsylvania 17033
Hospital of the University of Pennsylvania (PAUP) Philadelphia Pennsylvania 19104
Allegheny General Hospital (PAAG) Pittsburgh Pennsylvania 15212
Vanderbilt University Medical Center (TNVU) Nashville Tennessee 37232
Baylor University Medical Center (TXTX) Dallas Texas 75246
University of Utah (UTMC) Salt Lake City Utah 84132

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03644667, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 6, 2026 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03644667 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →